Potential benefits of high-dose methylprednisolone in acute spinal cord injuries

Orthopedics

Volumn 33, Issue 4, 2010, Pages

  Walsh, Kelly A ^a   Weant, Kyle A ^a   Cook, Aaron M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METHYLPREDNISOLONE; NALOXONE; TIRILAZAD; NEUROPROTECTIVE AGENT;

ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG UTILIZATION; FLUID RESUSCITATION; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION; MOTOR PERFORMANCE; NEUROPROTECTION; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PNEUMONIA; SEPSIS; SPINAL CORD INJURY; TREATMENT OUTCOME; WOUND INFECTION; DOSE RESPONSE; MULTICENTER STUDY; PREVALENCE;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; PREVALENCE; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 77952835733     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Spinal Cord Injury Facts and Figures at a Glance. National Spinal Cord Injury Statistical Center Web site. https://www.nscisc.uab.edu/public-content/ pdf/FactsApr09.pdf. Published April 2009. Accessed February 3, 2010.
2. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery. 2002; 50(3 Suppl):S63-S72. (Pubitemid 44178775)
3. Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976). 2001; 26(24 Suppl):S2-12.
4. Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008; 25 (5):E2.
5. Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRX. 2004; 1(1):80-100. (Pubitemid 46589342)
6. Rozet I. Methylprednisolone in acute spinal cord injury: Is there any other ethical choice? J Neurosurg Anesthesiol. 2008; 20(2):137-139. (Pubitemid 351440987)
7. Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. Brain. 2006; 129(Pt 12):3249-3269.
8. Tederko P, Krasuski M, Kiwerski J, Nyka I, Bialoszewski D. Strategies for neuroprotection following spinal cord injury. Ortop Traumatol Rehabil. 2009; 11(2):103-110.
9. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990; 322(20):1405-1411.
10. Hawryluk GW, Rowland J, Kwon BK, Fehlings MG. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus. 2008; 25(5):E14.
11. Dumont RJ, Verma S, Okonkwo DO, et al. Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin Neuropharmacol. 2001; 24(5):265-279. (Pubitemid 32906713)
12. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984; 251(1):45-52. (Pubitemid 14212880)
13. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997; 277(20):1597-1604.
14. Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976). 2001; 26(4):426-430. (Pubitemid 32184858)
15. Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord. 2000; 38(2):71-76. (Pubitemid 30153991)
16. Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992; 76(1):23-31.
17. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg. 1998; 89(5):699-706.
18. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001; 345(19):1359-1367.
19. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360(13):1283-1297.
20. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998; 338(12):791-797.
21. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999; 56(4):347-379.